Grace Therapeuticsincis A Late Stage Biopharmaceutical Company Dedicated To Developing Therapies For Rare And Orphan Diseasesparticularly Focusing On Neurological Conditionsthe Company Utilizes Innovative Drug Delivery Technologies To Enhance Existing Treatments And Holds Over 40 Granted And Pending Patents Worldwidewith A Team Of Approximately 32 Employeesgrace Therapeutics Is Committed To Addressing Significant Unmet Medical Needs The Company S Pipeline Includes Several Promising Candidatesgtx 104 Targets Aneurysmal Subarachnoid Hemorrhageasahwith An Intravenous Formulation Of Nimodipineaiming To Improve Treatment Administration For Unconscious Patientsgtx 102 Is An Oral Mucosal Betamethasone Spray For Ataxia Telangiectasiawhile Gtx 101 Is A Topical Bupivacaine Spray Designed For Postherpetic Neuralgiagrace Therapeutics Has Received Fda Orphan Drug Designation For Its Lead Candidateswhich Provides Seven Years Of U Smarketing Exclusivity Following Approval
